Previous section Next section
PURINE METABOLISM
Body_ID: HC029005
De novo synthesis of purine ring: inosine monophosphate (IMP)
Body_ID: HC029006
The de novo synthesis of IMP provides the cell with the capacity to construct the purine ring ab initio, thereby insuring a source of nucleotides for cellular processes. Figure 29.2 shows portions of the pathway of purine biosynthesis along with the metabolic origin of each of the atoms in the purine ring. Synthesis is an energy-demanding process. AdenosineView drug information 5'-triphosphate (ATP) is required at each of the kinase, synthetase, and ring-closure steps. The starting material for purine biosynthesis is ribose 5-phosphate, a product of the pentose phosphate pathway.
Body_ID: P029006
page 413
0
page 414
Body_ID: P0414
Body_ID: P029008
Body_ID: F029001
Figure 29.1 Classification of nucleotides. Basic structure of purines and pyrimidines.
Body_ID: T029001
Table 29-1. Names and structures of important purines and pyrimidines.
Body_ID: None
Names and structures of purines and pyrimidines
Body_ID: T029001.50
StructureFree baseNucleosideNucleotide
Body_ID: T029001.100
 adenineadenosineView drug informationAMP
ADP
ATP
cAMP
Body_ID: T029001.150
 guanineguanosineGMP
GDP
GTP
cGMP
Body_ID: T029001.200
 hypoxanthineinosineIMP
Body_ID: T029001.250
 uraciluridineUMP
UDP
UTP
Body_ID: T029001.300
 cytosinecytidineCMP
CDP
CTP
Body_ID: T029001.350
 thyminethymidineTMP
TDP
TTP
Body_ID: T029001.400
Body_ID: T029001.450
Body_ID: T029001

The designation NTP refers to the ribonucleotide. The prefix d, as in dATP, is used to identify deoxyribonucleotides. dTTP is usually written as TTP, with the d-prefix implied.
Body_ID: None
The first step, catalyzed by ribose phosphate pyrophosphokinase (PRPP synthetase), generates the activated form of pentose phosphate by transferring a pyrophosphate group from ATP to form 5-phosphoribosyl-pyrophosphate (PRPP). PRPP is also used in other biosynthetic reactions including nucleotide salvage and the biosynthesis of tryptophan and histidine.
Body_ID: P029007
In the second step, catalyzed by amidophosphoribosyl transferase, an amino group from glutamine displaces the pyrophosphate group. In a reaction that is similar to the formation of a peptide bond, glycineView drug information is added to the β-5-phosphoribosylamine to yield glycinamide ribonucleotide (GAR), catalyzed by GAR synthetase. The free amino group of GAR is then modified by addition of a formyl group by GAR transformylase to make formylglycinamide ribonucleotide (FGAR). The formyl group comes from N10-formyl tetrahydrofolate.
Body_ID: P029009
In step 5, a second amino group is added onto FGAR to form formylglycinamidine ribonucleotide (FGAM). As for other amino group additions, the donor is glutamine. The enzyme catalyzing this addition is termed FGAM synthetase. The imidazole ring is now closed to form 5-aminoimidazole ribonucleotide (AIR) by action of AIR synthetase.
Body_ID: P029010
The second 6-member ring is built by adding the three atoms, followed by cyclization. The first atom to be added is the C-6 carbon forming carboxyaminoimidazole ribonucleotide (CAIR). In an unusual reaction, catalyzed by AIR carboxylase, this carbon atom arises directly from CO2, without involvement of biotin. The nitrogen atom at position 1 of the mature purine ring is now added in a two-step reaction, using aspartate as the nitrogen donor. The first step is the formation of an aspartate-CAIR covalent intermediate termed 5-aminoimidazole-4-(N-succinylocarboxamide) ribonucleotide (SACAIR), catalyzed by SACAIR synthetase. The four-carbon dicarboxylic acid, fumarate, is then released from SACAIR by the action of adenylosuccinate lyase to form 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR).
Body_ID: P029011
The last purine-ring carbon is added as a formyl group from N10-formyl tetrahydrofolate, by AICAR transformylase; the product is 5-formylaminoimidazole-4-carboxamide ribonucleotide (FAICAR). Finally, IMP synthase catalyzes closure of the second purine ring to form IMP.
Body_ID: P029012
Previous section
Bar end Bar end
Next section
Copyright © 2007 Elsevier Inc. All rights reserved. Read our Terms and Conditions of Use and our Privacy Policy.
For problems or suggestions concerning this service, please contact: studentconsult.help@elsevier.com